RECRUITINGINTERVENTIONAL

Respiratory Dysbiosis in Preschool Children with Asthma: Predictive of a Severe Form

About This Trial

The prevalence of asthma in preschool children is between 11 and12%. Inhaled corticosteroid therapy is the main therapy used, however this treatment seems insufficiently effective in some children. Recent research in cystic fibrosis has made it possible to highlight pulmotypes corresponding to the different stages of pulmonary dysbiosis, and a predictive microbiological signature of an increased risk of early primocolonization to P. aeruginosa. These pulmotypes are the result of the so-called "enterotyping" analysis, a biostatistical method that makes it possible to stratify individuals according to the analysis of the microbiota. In the light of these data, it seems interesting to transcribe the concept of using a biomarker of the microbiota in the monitoring of a chronic lung disease such as asthma. The hypothesis is that there is respiratory dysbiosis causing corticosteroid resistance to treatment in children under 3 years of age with severe asthma.

Who May Be Eligible (Plain English)

Who May Qualify: - Age greater than 1 year and less than 3 years - Diagnosis of asthma by a pediatrician - Parental consent - Affiliation to the social security system Who Should NOT Join This Trial: - Chronic pathologies: congenital heart disease, immune deficiency, cystic fibrosis, bronchopulmonary dysplasia, encephalopathy, primary ciliary dyskinesia, laryngomalacia, digestive pathology requiring digestive surgery - Premature \< 34 SA - Recent antibiotic therapy (\< 7 days) - Treatment with oral corticosteroid therapy within the previous 10 days. - Patient whose parent(s) is (are) minor(s) Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Age greater than 1 year and less than 3 years * Diagnosis of asthma by a pediatrician * Parental consent * Affiliation to the social security system Exclusion Criteria: * Chronic pathologies: congenital heart disease, immune deficiency, cystic fibrosis, bronchopulmonary dysplasia, encephalopathy, primary ciliary dyskinesia, laryngomalacia, digestive pathology requiring digestive surgery * Premature \< 34 SA * Recent antibiotic therapy (\< 7 days) * Treatment with oral corticosteroid therapy within the previous 10 days. * Patient whose parent(s) is (are) minor(s)

Treatments Being Tested

PROCEDURE

Stool test

At inclusion (day 0), stools will be collected with a kit for to remove to 5 mg for each patient.

PROCEDURE

Blood test

Blood sample taken during inclusion (day 0) will be collected. There is between 19 and 26 mL for each patient.

PROCEDURE

Induced sputum

At inclusion (day 0), bronchial aspiration after inhalation induction of 4 mL of 6% salt serum administered (after 200 μg of salbutamol via an inhalation chamber during a bronchial drainage session).

PROCEDURE

nasale virology

At inclusion (Day 0), patients will be taken nasal swab for virology with swab adapted for nasal swab or with suction trap when blowing the child's nose (depending on center practice)and multiplex PCR.

Locations (1)

CHU de Brest

Brest, Finistère, France